3.260SEK-6.05%Mkt Cap: 343.98M SEKP/E: 3.47Last update: 2026-06-01
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various typ…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap343.98M SEK
Enterprise Value257.81M SEK
Revenue (TTM)153.10M SEK
Gross Profit154.09M SEK
Net Income (TTM)91.74M SEK
Revenue/Share1.508 SEK
Last Price3.260 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees30
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006343745
Valuation
P/E (Trailing)3.47
P/E (Forward)2.67
PEG—
EV/EBITDA2.89
EV/Revenue1.68
P/S2.39
P/B3.07
EPS (TTM)0.94
EPS (Forward)1.30
52W Range
0.401075% of range4.210
52W High4.210 SEK
52W Low0.4010 SEK
Profitability
Gross Margin92.18%
Oper. Margin-26998.11%
EBITDA Margin58.34%
Profit Margin54.88%
ROE76.97%
ROA67.13%
Growth
Revenue Growth-99.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF83.53M SEK
CapEx (TTM)94.00K SEK
FCF Margin27.43%
FCF Yield12.21%
Net Debt-108.33M SEK
Net Debt/EBITDA-1.21
Balance Sheet
Debt/Equity—
Current Ratio9.10
Quick Ratio9.10
Book Value/Sh1.129 SEK
Cash/Share1.027 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)4.800 SEK
Target Range4.800 SEK – 4.800 SEK
# Analysts1
Ownership
Shares Out.105.52M
Float70.62M
Insiders35.22%
Institutions31.75%
Technical
SMA 503.137 (+3.9%)
SMA 2001.701 (+91.6%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)620.05K
Avg Vol (10d)594.37K
Technical Indicators
RSI (14)52.0
MACD0.1060
MACD Signal0.1445
MACD Hist.-0.0385
BB Upper3.938 SEK
BB Middle3.535 SEK
BB Lower3.132 SEK
BB Width22.80%
ATR (14)0.3208 SEK
Vol Ratio (20d)0.80x